Generic Medicine Info
May be taken with or without food.
Severe hypotension, cardiogenic shock, left ventricular outflow tract obstruction (e.g. high-grade aortic stenosis), heart failure after acute MI.
Special Precautions
Patients with aortic stenosis, congestive heart failure, hypertrophic cardiomyopathy, outflow tract obstruction, severe obstructive coronary disease. Hepatic impairment. Elderly and children. Pregnancy and lactation. Patient Counselling This drug may cause dizziness, headache, fatigue or nausea, if affected, do not drive or operate machinery. Monitoring Parameters Monitor BP, heart rate, pulse, frequency and intensity of angina, weight, and peripheral oedema.
Adverse Reactions
Significant: Peripheral oedema, hypotension, angina/MI. Blood and lymphatic system disorders: Leucopenia, thrombocytopenia. Cardiac disorders: Bradycardia, ventricular tachycardia, chest pain, palpitation. Ear and labyrinth disorders: Tinnitus. Eye disorders: Visual disturbance, diplopia, conjunctivitis. Gastrointestinal disorders: Nausea, dyspepsia, diarrhoea, constipation, abdominal pain. General disorders and administration site conditions: Fatigue, asthenia. Investigations: Weight gain, elevated hepatic enzymes. Musculoskeletal and connective tissue disorders: Muscle cramps, arthralgia, back pain. Nervous system disorders: Headache, somnolence, dizziness, extrapyramidal symptoms. Psychiatric disorders: Insomnia, anxiety, depression. Renal and urinary disorders: Micturition disorder, nocturia. Reproductive system and breast disorders: Sexual dysfunction, gynaecomastia. Respiratory, thoracic and mediastinal disorders: Pulmonary oedema, dyspnoea, cough, rhinitis. Skin and subcutaneous tissue disorders: Rash, skin discolouration, pruritus. Vascular disorders: Flushing.
Drug Interactions
Increased systemic plasma concentration with immunosuppressants (e.g. ciclosporin, tacrolimus). Increased serum concentration of simvastatin. Increased exposure with CYP3A4 enzyme inhibitors (e.g. protease inhibitors, azole antifungals, erythromycin, diltiazem). Decreased plasma concentration with CYP3A4 inducers (e.g. rifampicin).
CIMS Class
Anti-Anginal Drugs / Calcium Antagonists
ATC Classification
C08CA01 - amlodipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on amlodipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in